

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLMIM.001CPI	APPLICATION NO. 09/380,534
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Kundig et al.	
		FILING DATE September 1, 1999	GROUP


## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>MTJ</i>	1	3,604,417	9/14/71	Stolzenberg et al.			
	2	3,929,132	12/30/75	Higuchi			
	3	4,286,067	8/25/81	Theeuwes			
	4	4,300,558	11/12/81	Eckenhoff et al.			
	5	4,340,048	7/20/82	Eckenhoff			
	6	4,435,173	3/6/84	Siposs et al.			
	7	4,439,199	3/27/84	Amkraut et al.			
	8	4,455,145	6/19/84	Theeuwes			
	9	4,498,843	2/12/85	Schneider et al.			
	10	4,526,569	7/2/85	Bernardi			
	11	4,561,856	12/31/85	Cochran			
	12	4,643,723	2/17/87	Smit			
	13	4,767,628		Hutchinson et al.			
	14	4,838,862	6/13/89	Baker et al.			
	15	4,865,598	9/12/89	Eckenhoff			
	16	4,908,433	3/13/90	Mertlesmann et al.			
	17	4,929,233	5/29/90	Roth et al.			
	18	5,023,088	6/11/91	Wong et al.			
	19	5,030,216	7/9/91	Theeuwes et al.			
	20	5,257,987	11/2/93	Athayde et al.			
	21	5,286,254	2/15/94	Shapland et al.			
	22	5,304,165	4/19/94	Haber et al.			
	23	5,368,562	11/29/94	Blomquist et al.			
	24	5,478,556	12/26/95	Elliott et al.			
	25	5,496,360	3/5/96	Hoffmann et al.			
<i>MTJ</i>	26	5,580,859	12/03/96	Felgner et al.			

RECEIVED  
OCT 17 2000  
TO 3700 MAIL ROOM

EXAMINER <i>Michael J Hayes</i>	DATE CONSIDERED <i>5/17/01</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLMIM.001CPI	APPLICATION NO. 09/380,534
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Kundig et al.	
		FILING DATE September 1, 1999	GROUP



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
MJH	27	5,589,466	12/31/96	Felgner et al.			
	28	5,679,647	10/21/97	Carson et al.			
	29	5,698,396	12/16/97	Pfreundschuh			
	30	5,733,548	03/31/98	Restifo et al.			
	31	5,744,316	4/28/98	Lethe et al.			
	32	5,747,269	5/5/98	Rammensee et al.			
	33	5,846,540	12/08/98	Restifo et al.			
	34	5,856,187	01/05/99	Restifo et al.			
	35	5,962,428	10/05/99	Carrano et al.			
MJH	36	6,037,135	03/14/00	Kubo et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
MJH	37	2,147,863	05/26/94	Canada				
	38	74899	08/13/97	Ireland				
	39	WO 92/21033	11/26/92	PCT				
	40	EP 93/03175	04/06/95	PCT				
	41	WO 95/17167	06/25/95	PCT				
	42	WO 96/01429	01/18/96	PCT				
	43	WO 96/27008	09/06/96	PCT				
	44	WO 96/40209	12/19/96	PCT				
	45	WO 98/13489	04/02/98	PCT				
	46	WO 98/14464	04/09/98	PCT				
	47	WO 98/27963	07/02/98	PCT				
MJH	48	WO 98/43611	10/08/98	PCT				

EXAMINER	Michael J Hayer	DATE CONSIDERED	5/12/01
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLIIMM.001CPI	APPLICATION NO. 09/380,534
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Kundig et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE September 1, 1999	GROUP

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
<i>MSH</i>	49 Bachman, M.F., et al. (1994) In vitro vs. in vivo assays for the assessment of T- and B cell function. Curr. Opin. Immunol. 6:320-326.
	50 Cleland, J.L., et al. (1994) Formulation and delivery of proteins and peptides. American Chemical Society, Acs Symposium Series No. 567.
	51 Durrant LG (1997) Cancer vaccines. Anti-cancer drugs. 8:727-733.
	52 Grohmann, U. et al. (1991) Intrasplenic immunization for the induction of humoral and cell-mediated immunity to nitrocellulose-bound antigen. Journal of Immunological Methods. 137:9-15.
	53 Haynes, B. F. et al. (1996) Toward an understanding of the correlates of protective immunity to HIV infection. Science. 271:324-327.
	54 Inaba, K., et al. (1992) Identification of proliferating dendritic cell precursors in mouse blood. Journal of Experimental Medicine. 175:1157-1167.
	55 Jager, E., et al. (1996) Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer. 67:54-62.
	56 Jager E. et al. (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding Peptide Epitopes. J.Exp.Med. 187:265-270.
	57 Kundig, T.M. et al. (1992) Skin test to assess virus-specific cytotoxic T-cell activity. Proc. Natl. Acad. Sci. 89:7757-7761.
	58 Kundig, T.M. et al. (1995) Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science. 268:1343-1347.
	59 Kundig, T.M. et al. (1996) On the role of antigen in maintaining cytotoxic T cell memory. Proc. Natl. Acad. Sci. 93:9716-9723.
	60 Moskopidhis D. et al. (1995) Immunobiology of Cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus. Journal of Virology. 69:4:2187-2193.
	61 Oehen S. et al. (1992) Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen. J.Exp.Med. 176:1273-1281.
	62 Oldstone, M. et al. (1995) Discriminated selection among viral peptides with the appropriate anchor residues: Implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection. Journal of Virology. 69:12:7423-7429.
	63 Pantaleo G. et al. (1997) Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc. Natl. Acad. Sci. 94:9848-9853.
	64 Peters, R.I. et al. (1984) Tryptophan and serotonin metabolism after sustained tryptophan infusion. Neurochem. Int. 6:5:685-691.
	65 Puccetti P. et al. (1994) Use of skin test assay to determine tumor-specific CD8+ T cell reactivity. Eur. J. Immunol. 24:1446-1452.
	66 Rammensee, H.G. et al. (1995) MHC ligands and peptide motifs: first listing. Immunogenetics.41:178-228.
	67 Rammensee, H.G. et al. (1997) MHC ligands and peptide motifs. Landes Bioscience Austin Texas. Chapter 4:217-369.
	68 Remington (1985) The science and practice of pharmacy, Nineteenth Edition: Chapters 86-88.
	69 Santus G. et al. (1995) Osmotic drug deliver: a review of patent literature. Journal of Controlled Release. 35:1-21.
	70 Speiser, D.E. et al. (1997) Self antigens expressed by solid tumors do not efficiently stimulate naïve or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645-653.
	71 Steinman R.M. (1991) The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271-296.
	72 Wiseman C. et al. (1993) Clinical responses to intralymphatic whole-cell melanoma vaccine augmented by in vitro incubation with alpha-interferon. Annals of the New York Academy of Sciences. 690:388-391.
	73 Wiseman C.L. et al. (1989) Clinical responses with active specific intralymphatic immunotherapy for cancer - A phase I-II trial. The Western Journal of Medicine. 151:283-288.
	74 Young J. W. et al. (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J.Exp.Med. 183:7-11.
<i>MSH</i>	75 Zipkin I. (1998) Cancer vaccines. BioCentury. 6:A1-A6.

S:\DOCS\IMKD\1275.DOC\061500

EXAMINER <i>Michael J. Hayer</i>	DATE CONSIDERED <i>5/17/01</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLIMM.001CP1	APPLICATION NO. 09/380,534
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Kundig, et al.	
		FILING DATE September 1, 1999	GROUP 3700

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>M/JH</i>		3,732,865	5-15-73	Higuchi, et al.			
		3,760,804	9-25-73	Higuchi, et al.			
		3,760,805	9-25-73	Higuchi			
		3,760,984	9-25-73	Theeuwes			
		3,987,790	10-26-76	Eckenhoff, et al.			
		3,995,631	12-7-76	Higuchi, et al.			
		3,995,632	12-7-76	Nakano, et al.			
		4,034,756	7-12-77	Higuchi, et al.			
		4,203,440	5-20-80	Theeuwes			
		4,304,232	12-8-81	Michaels			
		4,340,054	7-20-82	Michaels			
		4,350,271	9-21-82	Eckenhoff			
		4,367,741	1-11-83	Michaels			
		4,450,198	5-22-84	Michaels			
		4,474,575	10-2-84	Eckenhoff, et al.			
		4,619,652	10-28-86	Eckenhoff, et al.			
		4,753,651	6-28-88	Eckenhoff			
		4,855,141	8-8-89	Eckenhoff, et al.			
		4,865,845	9-12-89	Eckenhoff, et al.			
		4,872,873	10-10-89	Zingerman			
		4,898,582	2-6-90	Faste			
		4,963,141	10-16-90	Eckenhoff			
		4,976,966	12-11-90	Theeuwes, et al.			
		5,017,381	5-21-91	Maruyama, et al.			
		5,034,229	7-23-91	Magruder, et al.			
<i>M/JH</i>		5,037,420	8-6-91	Magruder, et al.			

EXAMINER <i>Michael J. Hayer</i>	DATE CONSIDERED <i>5/17/01</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLMIM.001CP1	APPLICATION NO. 09/380,534
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Kundig, et al.	
		FILING DATE September 1, 1999	GROUP 3700

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
MJH		5,057,318	10-15-91	Magruder, et al.			
		5,059,423	10-22-91	Magruder, et al.			
		5,110,596	5-5-92	Magruder, et al.			
		5,110,597	5-5-92	Wong, et al.			
		5,135,498	8-4-92	Kam, et al.			
		5,135,523	8-4-92	Magruder, et al.			
		5,137,727	8-11-92	Eckenhoff			
		5,169,390	12-8-92	Athayde, et al.			
		5,174,999	12-29-92	Magruder, et al.			
		5,209,746	5-11-93	Balaban, et al.			
		5,221,278	6-22-93	Linkwitz, et al.			
MJH		5,223,265	6-29-93	Wong			

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Pfeiffer, et al. "Insulin Pump Therapy" 3.1 to 3.2.4 pg. 14-33

S:\DOCS\MTM\MTM-1067.DOC:gem  
111300

EXAMINER <i>Michael Hayer</i>	DATE CONSIDERED <i>5/17/01</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	